论文部分内容阅读
[目的 ] 观察杜秘克 (Duphalac)对肝硬化患者血氨、智能测试、肝功能指标的疗效。 [方法 ] 72例患者随机分为治疗组和对照组。前者给予Duphalac口服 ,后者服用维生素C及复合维生素B ,治疗前及治疗后 2、4周 ,分别检测血氨、数字联接试验 (NCT)、肝功能指标。 [结果 ] 4周后 ,治疗组血氨 (中位数 )从 2 .15 (N -mg/L)降低到 1.36 (N -mg/L)、NCT(中位数 )从 10 0s降低到 5 6s。对照组血氨和NCT无明显变化。治疗组与对照组比较 ,P <0 .0 1。治疗组治疗前与治疗 4周后比较 ,P <0 .0 1。治疗组部分肝功能指标有所好转。 [结论 ] Duphalac能有效地改善亚临床肝性脑病(SHE)和避免肝性脑病 (HE)发生。
[Objective] To observe the effects of Duphalac on blood ammonia, intelligence test and liver function in cirrhotic patients. [Methods] 72 patients were randomly divided into treatment group and control group. The former was given Duphalac orally, the latter taking vitamin C and vitamin B complex, before and after treatment 2,4 weeks, respectively, detection of blood ammonia, digital connection test (NCT), liver function indicators. [Results] After 4 weeks, the blood ammonia in the treatment group decreased from 2.15 (N-mg / L) to 1.36 (N-mg / L) and the NCT (median) decreased from 10 0s to 5 6s. Blood ammonia and NCT had no significant change in the control group. The treatment group compared with the control group, P <0. The treatment group before treatment and after 4 weeks of treatment, P <0. Some liver function indicators improved in the treatment group. [Conclusion] Duphalac can effectively improve subclinical hepatic encephalopathy (SHE) and avoid the occurrence of hepatic encephalopathy (HE).